K252a inhibits proliferation of ovarian cancer cells by upregulating p21WAF1

Oncology Reports

Volumn 14, Issue 1, 2005, Pages 141-143

  Takai, Noriyuki ^a   Ueda, Tami ^a   Nishida, Masakazu ^a   Nasu, Kaei ^a   Fukuda, Junichiro ^a   Miyakawa, Isao ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle; Ovarian cancer

Indexed keywords

CARBAZOLE DERIVATIVE; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; K 252; PROTEIN KINASE C;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARBAZOLES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEIN KINASE C; UP-REGULATION;

EID: 24644444345     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Knusel B and Hefti F: K252a compounds: modulators of neurotrophin signal transduction. J Neurochem 59: 1987-1996, 1992.
2. Baltuch GH, Couldwell WT, Villemure J and Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines: a comparison between staurosporine and tamoxifen. Neurosurgery 33: 495-501, 1993. (Pubitemid 23260759)
3. Kase H, Iwahashi K and Matsuda Y: K-252a, a potent inhibitor of protein kinase C from microbial origin. J Antibiot 39: 1059-1065, 1986. (Pubitemid 16046365)
4. Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M, Murakata C, Sato A and Kaneko M: K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun 142: 436-440, 1987. (Pubitemid 17003365)
5. Nakanishi S, Yamada K, Kase H, Nakamura S and Nonomura Y: K-252a, a novel microbial product, inhibits smooth muscle myosin light chain kinase. J Biol Chem 263: 6215-6219, 1988.
6. 2+/calmodulin-dependent kinase II by K252a and its derivative, KT5926. Biochem Biophys Res Commun 181: 423-429, 1991.
7. Usui T, Yoshida M, Abe K, Osada H, Isono K and Beppu T: Uncoupled cell cycle without mitosis induced by protein kinase inhibitor, K252a. J Cell Biol 115: 1275-1282, 1991. (Pubitemid 21909973)
8. Koizumi S, Contreras ML, Matsuda Y, Hama T, Lazarovici P and Guroff G: K252a: a specific inhibitor of the action of nerve growth factor on PC12 cells. J Neurosci 8: 715-721, 1988. (Pubitemid 18078094)
9. Tapley P, Lamballe F and Barbacid M: K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 7: 371-381, 1992.
10. Nye SH, Squinto SP, Glass DJ, Stitt TN, Hantzopoulos P, Macchi MJ, Lindsay NS, Ip NY and Yancopoulos GD: K252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses Mol Biol Cell 3: 677-686, 1992. (Pubitemid 23098266)
11. Nakayama T, Hashimoto Y, Kaneko Y, Yoshida M, Beppu T, Ohmi K, Yamashita S, Nonomura Y and Kurokawa K: K252a: a new blocker of the cell-cycle at G1 phase in a human hepatoma cell line. Experientia 49: 876-880, 1993. (Pubitemid 23336618)
12. Chin LS, Murray SF, Zitnay KM and Rami B: K252a inhibits glioma proliferation by blocking PDGF signal transduction. Clin Cancer Res 3: 771-776, 1997. (Pubitemid 27244345)
13. Morotti A, Mila S, Accornero P, Tagliabue E and Ponzetto C: K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21: 4885-4893, 2002.
14. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I and Koeffler HP: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149, 2004. (Pubitemid 38198916)
15. 2+/calmodulin-dependent kinase IV expression in epithelial ovarian cancer. Cancer Lett 183: 185-193, 2002.
16. Shang S, Takai N, Nishida M, Miyazaki T, Nasu K and Miyakawa I: CaMKIV expression is associated with clinical stage and PCNA-labeling index in endometrial carcinoma. Int J Mol Med 11: 181-186, 2003.
17. 2+/calmodulin-dependent regulation of microtubule formation via phosphorylation of microtubule-associated protein 2, tau factor, and tubulin, and comparison with the cyclic AMP-dependent phosphorylation. J Neurochem 44: 759-768, 1985.
18. 2+/calmodulin-dependent protein kinase IV. Role in transcriptional regulation. J Biol Chem 269: 15520-15527, 1994.
19. Enslen H, Tokumitsu H and Soderling TR: Phosphorylation of CREB by CaM-kinase IV activated by CaM-kinase IV kinase. Biochem Biophys Res Commun 207: 1038-1043, 1995.
20. 2+/CaM kinase). Cell Growth Differ 6: 1063-1070, 1995.
21. Kawamura K, Grabowski D, Krivacic K, Hidaka H and Ganapathi R: Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem Pharmacol 52: 1903-1909, 1996. (Pubitemid 26419679)
22. Gotoh Y, Nishida E, Matsuda S, Shiina N, Kosako H, Shiokawa K, Akiyama T, Ohta K and Sakai H: In vitro effects on microtubule dynamics of purified Xenopus M phase-activated MAP kinase Nature 349: 251-254, 1991. (Pubitemid 21912059)
23. Freytag SO: Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1. Mol Cell Biol 8: 1614-1624, 1988.
24. Nakayama T, Hashimoto Y, Kaneko Y and Kurokawa K: K252a inhibits the phosphorylation of pRb without changing the levels of G1 cyclins and Cdk2 protein in human hepatoma cells. Biochem Biophys Res Commun 224: 180-183, 1996. (Pubitemid 26259613) Technology Technology